Candel Therapeutics, Inc. (NASDAQ:CADL) Receives $18.33 Average Target Price from Analysts

Candel Therapeutics, Inc. (NASDAQ:CADL) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $18.3333.

Several brokerages have recently commented on CADL. Wall Street Zen lowered Candel Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Lifesci Capital started coverage on shares of Candel Therapeutics in a report on Tuesday, October 21st. They issued an “outperform” rating and a $16.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a report on Wednesday, January 21st. Zacks Research downgraded shares of Candel Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, January 19th. Finally, Stephens reaffirmed an “overweight” rating and set a $15.00 price objective on shares of Candel Therapeutics in a research report on Monday, December 8th.

Institutional Trading of Candel Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. bought a new stake in shares of Candel Therapeutics in the 1st quarter worth approximately $59,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Candel Therapeutics by 37.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,748 shares of the company’s stock worth $95,000 after buying an additional 4,583 shares during the period. Rhumbline Advisers increased its position in Candel Therapeutics by 26.8% in the first quarter. Rhumbline Advisers now owns 33,302 shares of the company’s stock worth $188,000 after buying an additional 7,030 shares during the period. Janney Montgomery Scott LLC lifted its stake in Candel Therapeutics by 29.4% in the second quarter. Janney Montgomery Scott LLC now owns 27,290 shares of the company’s stock valued at $138,000 after buying an additional 6,200 shares during the last quarter. Finally, Tanager Wealth Management LLP acquired a new position in shares of Candel Therapeutics during the second quarter valued at $995,000. 13.93% of the stock is currently owned by institutional investors and hedge funds.

Candel Therapeutics Stock Performance

Shares of Candel Therapeutics stock opened at $5.93 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.25 and a current ratio of 8.25. Candel Therapeutics has a 1 year low of $4.25 and a 1 year high of $13.68. The firm’s 50-day simple moving average is $5.63 and its 200-day simple moving average is $5.64. The firm has a market cap of $325.56 million, a PE ratio of -10.40 and a beta of -0.93.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Equities analysts forecast that Candel Therapeutics will post -1.47 earnings per share for the current fiscal year.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.